Yes, OPHT is "intriguing", <g>
It is due to report its 2ndQ results tomorrow,
and that's always a dangerous time,
since its is always important that results and guidance beat the expectations.<g>
The stock has also been under some pressure by insiders taking some profits,
after exercising their options at lower prices.
I have a pretty good profit after my recent purchase,
and keep my trailing stop loss not too far, trying to protect it.<g>
FOVISTA can be used along with REGN's EYLEA,
and NVS is supposed to pay OPHT if the results of the PIII come out good.
Many people think NVS will buy OPHT.
Fidelity and Novo are among major holders.
OPHT also has Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD,
so yes, I agree that it is an "intriguing" Co., but just in case, will keep fingers crossed tomorrow<g> |
